Oleclumab clinical trials
Also written MEDI9447.
How each study uses oleclumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the oleclumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 10
AstraZeneca (5) · University Health Network, Toronto (3) · M.D. Anderson Cancer Center (2) · Jules Bordet Institute (2) · MedImmune LLC (2) · Assistance Publique Hopitaux De Marseille (1) · National Cancer Institute (NCI) (1) · Montefiore Medical Center (1)
Often tested with
Tested in the same studies.
Monalizumab (6) · Durvalumab (2) · Ceralasertib (2) · Danvatirsen (1) · Vistusertib (1) · Olaparib (1) · Trastuzumab deruxtecan (1) · Cediranib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test oleclumab, phase 3 first.
- Jan 2027A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPhase 3 · AstraZeneca
- Jun 2027Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses oleclumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Oleclumab
- Durvalumab and Oleclumab in Resectable PDACRecruitingPhase 2University Health Network, TorontoNCT06060405Written as Oleclumab
- The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2Not yet recruitingPhase 2Montefiore Medical CenterNCT07146230Written as Oleclumab
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingPhase 3AstraZenecaNCT05221840Written as Oleclumab
- Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04668300Written as Oleclumab
- Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active, not recruitingPhase 2Jules Bordet InstituteNCT03875573Written as Oleclumab
- Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04940286Written as Oleclumab
- Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCActive, not recruitingPhase 1/2Jules Bordet InstituteNCT03616886Written as MEDI9447
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingPhase 2AstraZenecaNCT06606847Written as Oleclumab
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Written as Oleclumab
- Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 TrialCompletedPhase 1National Cancer Institute (NCI)NCT03801902Written as Oleclumab
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedPhase 2MedImmune LLCNCT03822351Written as Durvalumab + Oleclumab
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440Written as Oleclumab (MEDI9447)
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedPhase 1/2MedImmune LLCNCT03611556Written as Oleclumab
- A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONWithdrawnPhase 2University Health Network, TorontoNCT04262375Written as Oleclumab
- A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnPhase 2University Health Network, TorontoNCT04262388Written as Oleclumab
- A Phase I Study of MEDI9447 (Oleclumab) in Japanese PatientsCompletedPhase 1AstraZenecaNCT03736473Written as MEDI9447 (oleclumab)
Given beside what is tested · 10 — oleclumab is usual care or a partner of the new treatment
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Written as Oleclumab
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingPhase 1/2MedImmune LLCNCT03381274Written as Oleclumab
- COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCActive, not recruitingPhase 1/2MedImmune LLCNCT04068610Written as Oleclumab
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingPhase 1AstraZenecaNCT03819465Written as Oleclumab
- An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerCompletedPhase 2AstraZenecaNCT04089553Written as Oleclumab
- MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedPhase 1MedImmune LLCNCT02503774Written as Oleclumab
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT02740985Written as Oleclumab
- A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)CompletedPhase 1Dana-Farber Cancer InstituteNCT03773666Written as Oleclumab
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.CompletedPhase 1MedImmune LLCNCT04261075Written as oleclumab
- Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedPhase 2MedImmune LLCNCT03794544Written as Oleclumab
Codes
What other systems call oleclumab · ClinicalTrials.gg INT015060
- UNII (FDA) 5CRY01URYQOLECLUMABConfirmed FDA, Wikidata
- Wikidata Q47123037oleclumabConfirmed FDA, Wikidata
- NCI Thesaurus C123914OleclumabOne source FDA
- DrugBank DB15088One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5CRY01URYQ | OLECLUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q47123037 | oleclumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C123914 | Oleclumab | One source FDA |
| DrugBank | DB15088 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.